Dr. Patrick Y. Lu founded and has led Sirnaomics from an early discovery startup to a siRNA therapeutics product company, with multiple programs currently at the clinical stage. Dr. Lu brings 25+ years of nucleic acid drug development experience at Novartis, Digene, and Intradigm, where he was a co-founder. He has helped Sirnaomics raising over $270 million and develop the novel siRNA therapeutic, STP705, for the treatment of cancer and fibrosis diseases.

Dr. Michael V. Molyneaux has unique experience of over 20 years in diversified clinical environments and industry, with proven results in clinical operations. Dr. Molyneaux is a board certified medical doctor and has completed his MBA. He was previously the CMO of Macrocure Inc. Dr. Molyneaux’s role is to help define therapeutic programs that will match the key properties of our lead product candidates. He is responsible for the development of clinical operations, medical affairs and regulatory affairs.

Dr. David Mark Evans has over 25 years of pharmaceutical drug discovery experience, primarily in oncology. Dr. Evans has worked in the RNAi field since 2003, holding senior management positions at Translational Genomics Research Institute and Dharmacon, Inc. (ThermoFisher Scientific, Inc.) prior to joining Sirnaomics. He also previously held positions at Serono Pharmaceuticals and Millennium Pharmaceuticals, Inc. He is responsible for scientific, technological, and research operations in oncology and fibrosis.

Dr. Zhifeng Long has 33+ years industrial experience directing translational research, drug development, pharmacotox studies, clinical research, molecular diagnostic assays, drug manufacturing, quality control and quality assurance. Prior to joining Siranomics in 2018, Dr. Long served for eight years as the president and chief executive officer at Personal Diagnostix, Inc. In his current role, he is responsible for delivery platform research and development and optimization, formulation development, analytical sciences as well as quality control and assurance.

Dr. Samarsky has been at the forefront of RNAi technology since 2001,supervising technology innovation and drug discovery teams in multiple international companies. Prior to joining Sirnaomics, he served as vice president of Technology Development at RXi Pharmaceuticals, USA, senior vice president of Technology and International Business Development at RiboBio, China, and chief scientific officer at Silence Therapeutics, Germany. He has authored more than 40 scientific papers, articles, book chapters, patents and patent applications, and has been an invited speaker at more than 100 international conferences.

Dr. Edward Yongxiang Wang has 25+ years of research experience and possesses in-depth knowledge of biopharmaceutical research and the IND and NDA processes. Prior to joining Sirnaomics, Dr. Wang served as the deputy general manager at Shanghai Furen Medicine R&D Co., Ltd. and the director of the vaccine production in Newlink Genetics Inc., for a special project to fight the Ebola epidemic. At Sirnaomics, he leads teams focused on manufacturing and regulatory compliance.

Dr. Welch has over 27 years of pharmaceutical and biotechnology experience with a focus on drug substance and drug product development and manufacturing. Dr. Welch has held leadership positions in both large and small companies including Emergent BioSolutions, where he held roles as vice president of Development Services and DVS site head within the CDMO business unit, as well as vice president for Process and Analytical Development in the Vaccines and BioDefense divisions.  He has also held leadership positions at Lonza Microbial US and Cambrex BioScience, Baltimore.

Dr. John Xu has worked in the industry from 1999. Before joining Sirnaomics in 2008, his career included positions at Novartis and Enzon. Dr. Xu graduated from Suzhou Medical College and Shanghai Second Medical University, was a Fogarty fellow in NIH (NHGRI). In addition to overseeing pre-clinical studies, Dr. Xu serves as General Manager of Sirnaomics Suzhou, one of Sirnaomics’ subsidiaries in China.

Mr. Wing Kei Yip has 12+ years of transaction experience in merger & acquisitions, initial public offerings, and private equity. Prior to joining Sirnaomics, Mr. Yip worked at Credit Suisse (Hong Kong) Ltd. from 2015 to 2018 and successively serving as an associate in the firm’s Investment Banking division and a vice president in the Ultra High Net Worth Entrepreneur Coverage department. In his current role, he manages the overall fundraising process for Sirnaomics and communication with the banking and investor communities.

Ms. Yun Zhang joined Sirnaomics in 2015 with responsibilities for the operation and management of Guangzhou Sirnaomics. She has served as the board secretary of Sirnaomics since 2018 and was appointed as the chief operating officer of Greater China in 2020. Prior to joining Sirnaomics, Ms. Zhang worked at the National Foundation for Cancer Research in Bethesda, Maryland from 2009 to 2015, with her last position serving as a program manager. She serves as a director and the vice president of marketing and communication of the Chinese Biopharmaceutical Association since 2013. In her current role, she is responsible for financing, listing execution, investor relations, and operation management affairs of Greater China of our Group.

Mr. George Ji has 30+ years of industrial business development and corporate management experience at multiple international firms, including GE, ASME, CHRG, and Quantum Communications. Prior to joining Sirnaomics, he served as managing director of a US listed biopharmaceutical company, where he was responsible for corporate affairs and US operations. In his current role, Mr. Ji manages the general operations of Sirnaomics, including corporate development, finance and accounting, human resources, and general administration.

Mr. John Buergenthal has 25+ years of human resource management experience in the biopharmaceutical industry. He is responsible for all HR functions within Sirnaomics, which includes talent acquisition, performance management, benefits, compensation, and payroll, and he has a lead role in corporate risk management. In his past leadership roles, Mr, Buergenthal built and oversaw the HR functions for several high growths and emerging biopharmaceutical companies including two public companies, Guilford Pharmaceuticals, and PharmAthene.